Latest Secondary hyperparathyroidism Stories
Third Phase 3 Study Met Non-Inferiority and Superiority Endpoints in the Reduction of Parathyroid Hormone THOUSAND OAKS, Calif., Feb.
-- Three multi-dose sizes designed to reduce drug waste, improve dosing efficiency -- LAKE FOREST, Ill., Nov. 5, 2014 /PRNewswire/ -- Hospira, Inc.
Second Phase 3 Registrational Study Meets Primary and All Secondary Endpoints THOUSAND OAKS, Calif., Aug.
Analysis Shows Study Met Primary and All Secondary Endpoints THOUSAND OAKS, Calif., July 17, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that a Phase 3 study evaluating
In one of the largest and longest trials involving patients with kidney failure, a study led by an international team of researchers found that cinacalcet — a drug commonly prescribed to patients with kidney failure and a disturbance of bone and mineral metabolism known as secondary hyperparathyroidism — does not significantly reduce the risk of death or major cardiovascular events.